{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:54:03Z","timestamp":1784037243820,"version":"3.55.0"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The major concern of today's time is the developing resistance in most of the\nclinically derived pathogenic micro-organisms for available drugs through several mechanisms. Therefore,\nthere is a dire need to develop novel molecules with drug-like properties that can be effective\nagainst the otherwise resistant micro-organisms.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods :<\/jats:title>\n<jats:p>New drugs can be developed using several methods like structure-based drug design, ligandbased\ndrug design, or by developing analogs of the available drugs to further improve their effects.\nHowever, the smartness is to opt for the techniques that have comparatively less expenditure, lower\nfailure rates, and faster discovery rates.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Analog-Based Drug Design (ABDD) is one such technique that researchers worldwide are\nopting to develop new drug-like molecules with comparatively lower market values. They start by first\ndesigning the analogs sharing structural and pharmacological similarities to the existing drugs. This\nmethod embarks on scaffold structures of available drugs already approved by the clinical trials, but\nare left ineffective because of resistance developed by the pathogens.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In this review, we have discussed some recent examples of anti-fungal and anti-bacterial\n(antimicrobial) drugs that were designed based on the ABDD technique. Also, we have tried to focus\non the in silico tools and techniques that can contribute to the designing and computational screening\nof the analogs, so that these can be further considered for in vitro screening to validate their better biological\nactivities against the pathogens with comparatively reduced rates of failure.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201021666200908121409","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T04:27:29Z","timestamp":1599625649000},"page":"1030-1045","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Growing Preferences towards Analog-based Drug Discovery"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-1309","authenticated-orcid":true,"given":"Mehak","family":"Dangi","sequence":"first","affiliation":[{"name":"Centre for Bioinformatics, M.D. University, Rohtak-124001, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3499-929X","authenticated-orcid":true,"given":"Alka","family":"Khichi","sequence":"additional","affiliation":[{"name":"Centre for Bioinformatics, M.D. University, Rohtak-124001, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-1831","authenticated-orcid":true,"given":"Ritu","family":"Jakhar","sequence":"additional","affiliation":[{"name":"Centre for Bioinformatics, M.D. University, Rohtak-124001, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-9394","authenticated-orcid":true,"given":"Anil K.","family":"Chhillar","sequence":"additional","affiliation":[{"name":"Centre for Bioinformatics, M.D. University, Rohtak-124001, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"11333","DOI":"10.3390\/molecules190811333","volume":"19","author":"Wang Y.","year":"2014","unstructured":"Wang Y.; Xu K.; Bai G.; Huang L.; Wu Q.; Pan W.; Yu S.; Synthesis and antifungal activity of novel triazole compounds containing piperazine moiety. Molecules 2014,19(8),11333-11340","journal-title":"Molecules"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.drudis.2006.02.006","volume":"11","author":"Wermuth C.G.","year":"2006","unstructured":"Wermuth C.G.; Similarity in drug: Reflections on analogue design. Drug Discov Today 2006,11,1359-6446","journal-title":"Drug Discov Today"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/0960-894X(96)00363-0","volume":"6","author":"Dickinson R.P.","year":"1996","unstructured":"Dickinson R.P.; Bell A.S.; Hitchcock C.A.; Narayanaswami S.; Ray S.J.D.; Richardson K.; Troke P.F.; Novel antifungal 2- aryl-1-(1h-1,2,4- triazole-1-yl) butan-2-ol derivatives with high activity against aspergillus. Bioorg Med Chem Lett 1996,6,2031-2036","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejmech.2004.03.004","volume":"39","author":"Upadhayaya R.S.","year":"2004","unstructured":"Upadhayaya R.S.; Jain S.; Sinha N.; Kishore N.; Chandra R.; Arora S.K.; Synthesis of novel substituted tetrazoles having antifungal activity. Eur J Med Chem 2004,39(7),579-592","journal-title":"Eur J Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1016\/j.bmc.2004.08.049","volume":"12","author":"Nam N.H.","year":"2004","unstructured":"Nam N.H.; Sardari S.; Selecky M.; Parang K.; Carboxylic acid and phosphate ester derivatives of fluconazole: Synthesis and antifungal activities. Bioorg Med Chem 2004,12(23),6255-6269","journal-title":"Bioorg Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12879-015-1282-4","volume":"15","author":"Fasugba O.","year":"2015","unstructured":"Fasugba O.; Gardner A.; Mitchell B.G.; Mnatzaganian G.; Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: A systematic review and meta-analysis of observational studies. BMC Infect Dis 2015,15,545","journal-title":"BMC Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1590\/S1678-9946201658053","volume":"58","author":"Reis A.C.","year":"2016","unstructured":"Reis A.C.; Santos S.R.; Souza S.C.; Saldanha M.G.; Pitanga T.N.; Oliveira R.R.; Ciprofloxacin resistance pattern among bacteria isolated from patients with community-acquired urinary tract infection. Rev Inst Med Trop S&#xE3;o Paulo 2016,58,53","journal-title":"Rev Inst Med Trop S&#xE3;o Paulo"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/jac\/dkw399","volume":"72","author":"Mulder M.","year":"2017","unstructured":"Mulder M.; Kiefte-de Jong J.C.; Goessens W.H.; de Visser H.; Hofman A.; Stricker B.H.; Verbon A.; Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. J Antimicrob Chemother 2017,72(1),281-289","journal-title":"J Antimicrob Chemother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1742-7843.2010.00602.x","volume":"107","author":"Birkett D.","year":"2010","unstructured":"Birkett D.; Br&#xF8;sen K.; Cascorbi I.; Gustafsson L.L.; Maxwell S.; Rago L.; Rawlins M.; Reidenberg M.; Sj&#xF6;qvist F.; Smith T.; Thuerman P.; Walubo A.; Orme M.; Sj&#xF6;qvist F.; Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 2010,107(1),531-559","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1248\/cpb.48.982","volume":"48","author":"Eto H.","year":"2000","unstructured":"Eto H.; Kaneko Y.; Sakamoto T.; New antifungal 1,2,4-triazoles with difluoro(heteroaryl)methyl moiety. Chem Pharm Bull (Tokyo) 2000,48(7),982-990","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1016\/j.tet.2006.09.021","volume":"62","author":"Porea V.S.","year":"2006","unstructured":"Porea V.S.; Ahera N.G.; Kumar M.; Shukla P.K.; Design and synthesis of fluconazole\/bile acid conjugate using click reaction. Tetrahedron 2006,62,11178-11186","journal-title":"Tetrahedron"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2217\/fmb.14.32","volume":"9","author":"Calderone R.","year":"2014","unstructured":"Calderone R.; Sun N.; Gay-Andrieu F.; Groutas W.; Weerawarna P.; Prasad S.; Alex D.; Li D.; Antifungal drug discovery: The process and outcomes. Future Microbiol 2014,9(6),791-805","journal-title":"Future Microbiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.bmcl.2007.04.038","volume":"17","author":"Lebouvier N.","year":"2007","unstructured":"Lebouvier N.; Pagniez F.; Duflos M.; Le Pape P.; Na Y.M.; Le Baut G.; Le Borgne M.; Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. Bioorg Med Chem Lett 2007,17(13),3686-3689","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bmc.2009.10.041","volume":"18","author":"Omar K.","year":"2010","unstructured":"Omar K.; Geronikaki A.; Zoumpoulakis P.; Camoutsis C.; Sokovi\u0107 M.; Ciri\u0107 A.; Glamoclija J.; Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg Med Chem 2010,18(1),426-432","journal-title":"Bioorg Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1016\/j.ejmech.2011.07.010","volume":"46","author":"Zhang Y.Y.","year":"2011","unstructured":"Zhang Y.Y.; Mi J.L.; Zhou C.H.; Zhou X.D.; Synthesis of novel fluconazoliums and their evaluation for antibacterial and antifungal activities. Eur J Med Chem 2011,46(9),4391-4402","journal-title":"Eur J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1128\/AAC.00229-15","volume":"59","author":"Shrestha S.K.","year":"2015","unstructured":"Shrestha S.K.; Fosso M.Y.; Green K.D.; Garneau-Tsodikova S.; Amphiphilic tobramycin analogues as antibacterial and antifungal agents. Antimicrob Agents Chemother 2015,59(8),4861-4869","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1002\/anie.201200761","volume":"51","author":"Herzog I.M.","year":"2012","unstructured":"Herzog I.M.; Green K.D.; Berkov-Zrihen Y.; Feldman M.; Vidavski R.R.; Eldar-Boock A.; Satchi-Fainaro R.; Eldar A.; Garneau-Tsodikova S.; Fridman M.; 6\u2032'-Thioether tobramycin analogues: Towards selective targeting of bacterial membranes. Angew Chem Int Ed Engl 2012,51(23),5652-5656","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cmdc.201600236","volume":"11","author":"Ngo H.X.","year":"2016","unstructured":"Ngo H.X.; Shrestha S.K.; Garneau-Tsodikova S.; Identification of ebsulfur analogues with broad-spectrum antifungal activity. ChemMedChem 2016,11(14),1507-1516","journal-title":"ChemMedChem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00044-019-02317-5","volume":"28","author":"Huerta A.Z.","year":"2019","unstructured":"Huerta A.Z.; Castaneda D.D.C.; Renedo J.B.; Zeron H.M.; Fernandez R.C.M.; Romero S.P.; Rodriguez M.M.; Uribe B.A.F.; Rivas N.G.; Yanez E.C.; Synthesis and in vitro biological evaluation of 1,3-bis-(1,2,3-triazol1-yl)-propan-2-ol derivatives as antifungal compounds&#x232A;uconazole analogues. Med Chem Res 2019,28,571-579","journal-title":"Med Chem Res"},{"key":"ref=20","author":"Cruz K.S.","unstructured":"Cruz K.S.; Lima E.S.; Silva M.D.J.A.D.; Souza E.S.D.; Montoia A.; Pohlit A.M.; Souza J.V.B.D.;  Screening and antifungal activity of a &#x3B2; -carboline derivative against Cryptococcus neoformans and C. gattii. Int. J. Microbiol. Res., 2019, Article ID 7157845."},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/psc.2674","volume":"20","author":"Bezzerri V.","year":"2014","unstructured":"Bezzerri V.; Avitabile C.; Dechecchi M.C.; Lampronti I.; Borgatti M.; Montagner G.; Cabrini G.; Gambari R.; Romanelli A.; Antibacterial and anti-inflammatory activity of a temporin B peptide analogue on an in vitro model of cystic fibrosis. J Pept Sci 2014,20,822-830","journal-title":"J Pept Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/jac\/dkx132","volume":"72","author":"Amoh T.","year":"2017","unstructured":"Amoh T.; Murakami K.; Kariyama R.; Hori K.; Viducic D.; Hirota K.; Igarashi J.; Suga H.; Parsek M.R.; Kumon H.; Miyake Y.; Effects of an auto inducer analogue on antibiotic tolerance in Pseudomonas aeruginosa. J Antimicrob Chemother 2017,72(8),2230-2240","journal-title":"J Antimicrob Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41598-018-19434-7","volume":"8","author":"Kim M.K.","year":"2018","unstructured":"Kim M.K.; Kang H.K.; Ko S.J.; Hong M.J.; Bang J.K.; Seo C.H.; Park Y.; Mechanisms driving the antibacterial and antibiofilm properties of Hp1404 and its analogue peptides against multidrug-resistant Pseudomonas aeruginosa. Sci Rep 2018,8(1),1763","journal-title":"Sci Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejmech.2018.11.056","volume":"163","author":"Teske K.A.","year":"2019","unstructured":"Teske K.A.; Dash R.C.; Morel S.R.; Chau L.Q.; Wechsler-Reya R.J.; Hadden M.K.; Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. Eur J Med Chem 2019,163,320-332","journal-title":"Eur J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2174\/1871527313666141023141545","volume":"13","author":"Mushtaq G.","year":"2014","unstructured":"Mushtaq G.; Greig N.H.; Khan J.A.; Kamal M.A.; Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer\u2019s disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014,13(8),1432-1439","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.bmc.2018.01.029","volume":"26","author":"Gurjar A.S.","year":"2018","unstructured":"Gurjar A.S.; Darekar M.N.; Yeong K.Y.; Ooi L.; In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer\u2019s disease. Bioorg Med Chem 2018,26(8),1511-1522","journal-title":"Bioorg Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/molecules24071437","volume":"24","author":"Ravichandiran P.","year":"2019","unstructured":"Ravichandiran P.; Sheet S.; Premnath D.; Kim A.R.; Yoo D.J.; 1,4-naphthoquinone analogues: Potent antibacterial agents and mode of action evaluation. Molecules 2019,24(7),1437","journal-title":"Molecules"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/cmdc.201800749","volume":"14","author":"Ravichandiran P.","year":"2019","unstructured":"Ravichandiran P.; Subramaniyan S.A.; Kim S.Y.; Kim J.S.; Park B.H.; Shim K.S.; Yoo D.J.; Synthesis and anticancer evaluation of novel 1,4-naphthoquinone derivatives containing a phenylamino-sulfanyl moiety. ChemMedChem 2019,14(5),532-544","journal-title":"ChemMedChem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1021\/acs.jmedchem.9b00616","volume":"62","author":"Deng Y.","year":"2019","unstructured":"Deng Y.; Weng X.; Li Y.; Su M.; Wen Z.; Ji X.; Ren N.; Shen B.; Duan Y.; Huang Y.; Late-stage functionalization of platensimycin leading to multiple analogues with improved antibacterial activity in vitro and in vivo. J Med Chem 2019,62(14),6682-6693","journal-title":"J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.aaj2191","volume":"355","author":"Levin-Reisman I.","year":"2017","unstructured":"Levin-Reisman I.; Ronin I.; Gefen O.; Braniss I.; Shoresh N.; Balaban N.Q.; Antibiotic tolerance facilitates the evolution of resistance. Science 2017,355(6327),826-830","journal-title":"Science"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1126\/science.aad9450","volume":"351","author":"Sprenger M.","year":"2016","unstructured":"Sprenger M.; Fukuda K.; Antimicrobial resistance. New mechanisms, new worries. Science 2016,351(6279),1263-1264","journal-title":"Science"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature17042","volume":"529","author":"Brown E.D.","year":"2016","unstructured":"Brown E.D.; Wright G.D.; Antibacterial drug discovery in the resistance era. Nature 2016,529(7586),336-343","journal-title":"Nature"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/CMR.00030-10","volume":"24","author":"Silver L.L.","year":"2011","unstructured":"Silver L.L.; Challenges of antibacterial discovery. Clin Microbiol Rev 2011,24(1),71-109","journal-title":"Clin Microbiol Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1021\/jm000153x","volume":"43","author":"Fang K.C.","year":"2000","unstructured":"Fang K.C.; Chen Y.L.; Sheu J.Y.; Wang T.C.; Tzeng C.C.; Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives. J Med Chem 2000,43(20),3809-3812","journal-title":"J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1021\/jm501881c","volume":"58","author":"Bisacchi G.S.","year":"2015","unstructured":"Bisacchi G.S.; Origins of the quinolone class of antibacterials: An expanded &#x201C;discovery story&#x201D;. J Med Chem 2015,58(12),4874-4882","journal-title":"J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejmech.2019.01.072","volume":"167","author":"Wang L.L.","year":"2019","unstructured":"Wang L.L.; Battini N.; Bheemanaboina R.R.Y.; Zhang S.L.; Zhou C.H.; Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation. Eur J Med Chem 2019,167,105-123","journal-title":"Eur J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1039\/C8MD00613J","volume":"10","author":"Abouelhassan Y.","year":"2019","unstructured":"Abouelhassan Y.; Zhang P.; Ding Y.; Huigens I.R.W.; Rapid kill assessment of an N-arylated NH125 analogue against drug-resistant microorganisms. MedChemComm 2019,10(5),712-716","journal-title":"MedChemComm"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.bmc.2019.02.025","volume":"27","author":"Blaser A.","year":"2019","unstructured":"Blaser A.; Sutherland H.S.; Tong A.S.T.; Choi P.J.; Conole D.; Franzblau S.G.; Cooper C.B.; Upton A.M.; Lotlikar M.; Denny W.A.; Palmer B.D.; Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline. Bioorg Med Chem 2019,27(7),1283-1291","journal-title":"Bioorg Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.4155\/fmc.11.79","volume":"3","author":"Guillemont J.","year":"2011","unstructured":"Guillemont J.; Meyer C.; Poncelet A.; Bourdrez X.; Andries K.; Diarylquinolines, synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207. Future Med Chem 2011,3(11),1345-1360","journal-title":"Future Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1021\/acsmedchemlett.7b00196","volume":"8","author":"Tong A.S.T.","year":"2017","unstructured":"Tong A.S.T.; Choi P.J.; Blaser A.; Sutherland H.S.; Tsang S.K.Y.; Guillemont J.; Motte M.; Cooper C.B.; Andries K.; Van den Broeck W.; Franzblau S.G.; Upton A.M.; Denny W.A.; Palmer B.D.; Conole D.; 6-Cyano analogues of bedaquiline as less lipophilic and potentially saferdiaryl quinolones for tuberculosis. ACS Med Chem Lett 2017,8(10),1019-1024","journal-title":"ACS Med Chem Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","volume":"92","author":"Collin F.","year":"2011","unstructured":"Collin F.; Karkare S.; Maxwell A.; Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl Microbiol Biotechnol 2011,92(3),479-497","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jac\/dkg208","volume":"51","author":"Emmerson A.M.","year":"2003","unstructured":"Emmerson A.M.; Jones A.M.; The quinolones: Decades of development and use. J Antimicrob Chemother 2003,51(Suppl. 1),13-20","journal-title":"J Antimicrob Chemother"},{"key":"ref=43","first-page":"2741","volume":"61","author":"King D.E.","year":"2000","unstructured":"King D.E.; Malone R.; Lilley S.H.; New classification and update on the quinolone antibiotics. Am Fam Physician 2000,61(9),2741-2748","journal-title":"Am Fam Physician"},{"key":"ref=44","first-page":"455","volume":"65","author":"Oliphant C.M.","year":"2002","unstructured":"Oliphant C.M.; Green G.M.; Quinolones: A comprehensive review. Am Fam Physician 2002,65(3),455-464","journal-title":"Am Fam Physician"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00277-013-1693-5","volume":"92","author":"Ping B.","year":"2013","unstructured":"Ping B.; Zhu Y.; Gao Y.; Yue C.; Wu B.; Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: A systematic review and meta-analysis. Ann Hematol 2013,92(6),831-839","journal-title":"Ann Hematol"},{"key":"ref=46","first-page":"87","volume":"V","author":"Vardanyan R.","year":"2016","unstructured":"Vardanyan R.; Hruby V.; Antipsychotics. Synthesis of Best-Seller Drugs. Elsevier B 2016,V,87-110","journal-title":"Elsevier B"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2165\/00003495-199957010-00004","volume":"57","author":"Slater J.W.","year":"1999","unstructured":"Slater J.W.; Zechnich A.D.; Haxby D.G.; Second-generation antihistamines: A comparative review. Drugs 1999,57(1),31-47","journal-title":"Drugs"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1056\/NEJM200301093480218","volume":"348","author":"Benhamou Y.","year":"2003","unstructured":"Benhamou Y.; Tubiana R.; Thibault V.; Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003,348(2),177-178","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"Ray A.S.","year":"2016","unstructured":"Ray A.S.; Fordyce M.W.; Hitchcock M.J.; Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res 2016,125,63-70","journal-title":"Antiviral Res"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169228","volume":"11","author":"Huang Y.S.","year":"2016","unstructured":"Huang Y.S.; Chang S.Y.; Sheng W.H.; Sun H.Y.; Lee K.Y.; Chuang Y.C.; Su Y.C.; Liu W.C.; Hung C.C.; Chang S.C.; Virological response to tenofovirdisoproxilfumarate in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection in an area hyperendemic for hepatitis B virus infection. PLoS One 2016,11(12)","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2017.51","volume":"8","author":"Lam Y.F.","year":"2017","unstructured":"Lam Y.F.; Seto W.K.; Wong D.; Cheung K.S.; Fung J.; Mak L.Y.; Yuen J.; Chong C.K.; Lai C.L.; Yuen M.F.; Seven-year treatment outcome of entecavir in a real-world cohort: Effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol 2017,8(10)","journal-title":"Clin Transl Gastroenterol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1756283X13515825","volume":"7","author":"Stedman C.","year":"2014","unstructured":"Stedman C.; Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: A review of its clinical potential. Therap Adv Gastroenterol 2014,7(3),131-140","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","volume":"4","author":"De Clercq E.","year":"2005","unstructured":"De Clercq E.; Hol&#xFD; A.; Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat Rev Drug Discov 2005,4(11),928-940","journal-title":"Nat Rev Drug Discov"},{"key":"ref=54","year":"2020","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury2020 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548938\/"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"Ferreira L.G.","year":"2015","unstructured":"Ferreira L.G.; Dos Santos R.N.; Oliva G.; Andricopulo A.D.; Molecular docking and structure-based drug design strategies. Molecules 2015,20(7),13384-13421","journal-title":"Molecules"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrd3375","volume":"10","author":"Arrowsmith J.","year":"2011","unstructured":"Arrowsmith J.; Trial watch: Phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011,10(2),87","journal-title":"Nat Rev Drug Discov"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","volume":"12","author":"Arrowsmith J.","year":"2013","unstructured":"Arrowsmith J.; Miller P.; Trial watch: Phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov 2013,12(8),569","journal-title":"Nat Rev Drug Discov"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/nsr\/nww003","volume":"3","author":"Liu T.","year":"2016","unstructured":"Liu T.; Lu D.; Zhang H.; Zheng M.; Yang H.; Xu Y.; Luo C.; Zhu W.; Yu K.; Jiang H.; Applying high-performance computing in drug discovery and molecular simulation. Natl Sci Rev 2016,3(1),49-63","journal-title":"Natl Sci Rev"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2015.00197","volume":"6","author":"Wasko M.J.","year":"2015","unstructured":"Wasko M.J.; Pellegrene K.A.; Madura J.D.; Surratt C.K.; A role for fragment-based drug designing developing novel lead compounds for central nervous system targets. Front Neurol 2015,6,1-11","journal-title":"Front Neurol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.13172\/2054-4057-1-1-1119","volume":"1","author":"Wadood A.","year":"2013","unstructured":"Wadood A.; In silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design Deliv 2013,1(1),3","journal-title":"OA Drug Design Deliv"},{"key":"ref=61","first-page":"277","volume":"2","author":"Bernard D.","year":"2005","unstructured":"Bernard D.; Coop A.; MacKerell, A.D. Jr. Computer-aided drug design: Structure-activity relationships of delta opioid ligands. Drug Des Rev 2005,2,277-291","journal-title":"Drug Des Rev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/j.1460-2075.1986.tb04288.x","volume":"5","author":"Chothia C.","year":"1986","unstructured":"Chothia C.; Lesk A.M.; The relation between the divergence of sequence and structure in proteins. EMBO J 1986,5(4),823-826","journal-title":"EMBO J"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1359-6446(97)01163-X","volume":"3","author":"Walters W.P.","year":"1998","unstructured":"Walters W.P.; Stahl M.T.; Murcko M.A.; Virtual screening \u2013 an overview. Drug Discov Today 1998,3(4),160-178","journal-title":"Drug Discov Today"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199601)16:1<3:AID-MED1>3.0.CO;2-6","volume":"16","author":"Bohacek R.S.","year":"1996","unstructured":"Bohacek R.S.; McMartin C.; Guida W.C.; The art and practice of structure-based drug design: A molecular modeling perspective. Med Res Rev 1996,16(1),3-50","journal-title":"Med Res Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/(SICI)1098-1128(199905)19:3<249:AID-MED4>3.0.CO;2-0","volume":"19","author":"K&#xF6;vesdi I.","year":"1999","unstructured":"K&#xF6;vesdi I.; Dominguez-Rodriguez M.F.; Orfi L.; N&#xE1;ray-Szab&#xF3; G.; Varr&#xF3; A.; Papp J.G.; M&#xE1;tyus P.; Application of neural networks in structure-activity relationships. Med Res Rev 1999,19(3),249-269","journal-title":"Med Res Rev"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1359-6446(97)01099-4","volume":"2","author":"Kennedy T.","year":"1997","unstructured":"Kennedy T.; Managing the drug discovery\/development interface. Drug Discov Today 1997,2,436-444","journal-title":"Drug Discov Today"},{"key":"ref=67","first-page":"33","volume":"5","author":"van de Waterbeemd H.","year":"2002","unstructured":"van de Waterbeemd H.; High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr Opin Drug Discov Devel 2002,5(1),33-43","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref=68","author":"Lesk A.J.M.","year":"2002","unstructured":"Lesk A.J.M.;  Introduction to bioinformatics 2002","journal-title":"Introduction to bioinformatics"},{"key":"ref=69","first-page":"47","author":"Perdo H.L.","year":"2010","unstructured":"Perdo H.L.;  A systematic review on CADD: Docking and Scoring 2010,47-51","journal-title":"A systematic review on CADD: Docking and Scoring"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.13172\/2054-4057-1-1-1119","volume":"1","author":"Wadood A.","year":"2013","unstructured":"Wadood A.; Ahmed N.; Shah L.; Ahmad A.; Hassan H.; Shams S.; In silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design  2013,1(1),3","journal-title":"OA Drug Design"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/pr.112.007336","volume":"66","author":"Sliwoski G.","year":"2013","unstructured":"Sliwoski G.; Kothiwale S.; Meiler J.; Lowe E.W.; Computational methods in drug discovery. Pharmacol Rev 2013,66(1),334-395","journal-title":"Pharmacol Rev"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bcp.12341","volume":"79","author":"Kimko H.","year":"2015","unstructured":"Kimko H.; Pinheiro J.; Model-based clinical drug development in the past, present and future: A commentary. Br J Clin Pharmacol 2015,79(1),108-116","journal-title":"Br J Clin Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/2229-3485.184782","volume":"7","author":"Gill S.K.","year":"2016","unstructured":"Gill S.K.; Christopher A.F.; Gupta V.; Bansal P.; Emerging role of bioinformatics tools and software in evolution of clinical research. Perspect Clin Res 2016,7(3),115-122","journal-title":"Perspect Clin Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"Wong C.H.","year":"2019","unstructured":"Wong C.H.; Siah K.W.; Lo A.W.; Estimation of clinical trial success rates and related parameters. Biostatistics 2019,20(2),273-286","journal-title":"Biostatistics"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201021666200908121409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185722\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201021666200908121409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T08:01:53Z","timestamp":1655798513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185722\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201021666200908121409","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}